Alpha Tau Medical (DRTS) 2nd Annual Lytham Partners Healthcare Investor Summit summary

Technology overview and clinical focus

• Alpha DaRT enables direct delivery of alpha particles into solid tumors, offering potent, localized radiation with minimal doses compared to traditional therapies.

• Preclinical studies across 20 tumor types showed universal response, leading to clinical focus on resistant tumors and those with high unmet need, such as pancreas and brain.

• Evidence suggests treatment may trigger immune recognition, potentially aiding systemic tumor control.

Clinical progress and regulatory strategy

• Pivotal study in recurrent cutaneous squamous cell carcinoma (SCC) is nearing completion, with patient recruitment targeted to finish in Q1 2026 and data expected later in the year.

• FDA allowed a modular PMA submission, enabling early review of preclinical and manufacturing modules before clinical data is finalized.

Key data and new indications

• Pancreatic cancer study in Montreal showed 100% feasibility, strong safety, over 80% disease control, and notable anti-inflammatory effects, with IL-6 levels dropping significantly.

• First glioblastoma patient treated at Ohio State achieved 95% tumor coverage with a favorable safety profile.